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Introduction
Considerable advances have been made in recent years in
understanding the genetics and molecular biology of
breast cancer, but for women in most western countries,
breast cancer still remains a major cause of death. The
majority of breast tumors are initially dependent upon
estrogen to support their growth, with the highest inci-
dence of breast cancer occurring in postmenopausal
women at a time when ovarian production of estrogens
has ceased. In this group of women estrogens continue to
be produced in extraglandular (i.e. non-ovarian) sites, such
as adipose tissue [1] but also in normal and malignant
breast tissues [2]. There is now convincing evidence from
a number of studies that concentrations of the biologically
active estrogen, estradiol, are higher in malignant than in
normal breast tissue [3,4]. Furthermore, the levels of estra-
diol that are detected in breast tumors are 50 to 100-fold
higher than the concentrations of this hormone that are
found in the circulation of postmenopausal women.
The high estradiol concentrations found in breast tumors
could arise either due to uptake from the circulation or
from in situ synthesis. As similar concentrations of estra-
diol are present in tumors with or without estrogen recep-
tors, in situ synthesis is now considered to be the major
pathway by which tumor estrogens originate. In this paper
we review the evidence implicating cytokines, and other
factors, in regulating the activities of the enzymes that are
involved in estrogen synthesis in breast tissues. The identi-
fication of cytokines as having a critical role in regulating
estrogen synthesis in peripheral tissues has suggested
mechanisms by which some known risk factors for breast
cancer (e.g. obesity, stress) may act to increase estrogen
synthesis within the breast.
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Abstract
Cytokines, such as IL-6 and tumor necrosis factor (TNF)-α, have an important role in regulating
estrogen synthesis in peripheral tissues, including normal and malignant breast tissues. The activities
of the aromatase, estradiol 17β-hydroxysteroid dehydrogenase and estrone sulfatase are all increased
by IL-6 and TNF-α. Prostaglandin E2 may also be an important regulator of aromatase activity in breast
tumors. Macrophages and lymphocytes, which invade many breast tumors, are thought to be an
important source of factors that can stimulate estrogen synthesis in malignant breast tissues. The co-
ordinated stimulation of the activities of the enzymes that are involved in estrogen synthesis offers an
explanation for the high concentrations of estrogens that are present in breast tumors.
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Estrogen synthesis in normal and malignant
breast tissues
Three main enzyme complexes are involved in the synthesis
of estrogens in peripheral tissues: aromatase is responsi-
ble for the aromatisation of androstenedione to estrone;
estrone sulfatase (E1-STS) catalyses the formation of
estrone from estrone sulfate; and estradiol-17β-hydroxys-
teroid dehydrogenase (17β-HSD) Type 1 is responsible for
the reduction of estrone to the biologically active estrogen,
estradiol. In addition, other enzymes, including 17β-HSD
Type 2 which inactivates estradiol, and estrone sulfotrans-
ferase, which renders estrogens inactive through sulfate
conjugation, are also important in regulating the tissue-
specificity and ligand availability of estrogenic hormones.
Aromatase
The aromatase enzyme, CYP19 P450(AROM), belongs to a
family of P450 enzymes [5]. In post menopausal women it
is located mainly in adipose tissue but is also present in
normal and malignant breast tissues. Immunocytochemical
studies to examine the location of aromatase in breast
tumors have provided evidence for a stromal [6] and
epithelial location [7]. Measurements of aromatase activity
in fibroblasts derived from breast tumors or MCF-7 cells,
however, have revealed a much higher level of aromatase
activity in fibroblasts [8].
Aromatase activity in breast tissues is relatively low, and
there has been considerable debate as to whether suffi-
cient estrogen could be produced to evoke a biological
response (i.e. stimulate tumor growth). Studies in women
with breast cancer revealed, in fact, that a major propor-
tion of breast tumor estrogen is synthesized in situ [9] and
that this is almost completely abolished by the potent aro-
matase inhibitors that are now in clinical use [10].
A breakthrough in understanding the control of aromatase
activity in breast cancer was made by Miller and colleagues
[11]. They were the first to show that the location of a
tumor within the breast influenced aromatase activity in the
quadrant in which the tumor was located. This finding,
which was subsequently confirmed at the expression and
activity levels, suggested either that tumors developed in
an area of high aromatase activity within the breast or that
tumors were capable of producing factors that stimulated
aromatase activity in adjacent tissues. Over the last decade
many studies have been carried out to identify potential
aromatase stimulatory factors. The analysis of breast cyst
fluid initially led to the identification of several factors that
could stimulate aromatase activity; IL-6 was the most
potent factor detected [12]. Cultured fibroblasts derived
from normal or malignant breast tissue were also found to
be a rich source of IL-6. The ability of IL-6 to stimulate aro-
matase activity was subsequently shown to be markedly
potentiated by the IL-6 soluble receptor [13]. This soluble
receptor is produced by fibroblasts from malignant, but not
normal, breast tissue, malignant breast epithelial cells and
cells of the immune system [13]. Other cytokines and
growth factors that can stimulate aromatase activity include
TNF-α, oncostatin M, leukaemia inhibitory factor and
insulin-like growth factor Type I [14].
The aromatase gene is expressed in several tissues in the
body (e.g. ovary and placenta) in addition to peripheral
tissues. It is now known that expression of the aromatase
gene is regulated in a tissue-specific manner by the use of
alternative promoters [15]. In adipose tissue its expression
is regulated mainly from promoter (P) I.4; PII and PI.3 have
lesser roles [16]. The 5′-upstream region of PI.4 contains
a glucocorticoid response element and an IFN-γ activating
sequence element which can bind transcription factors of
the ‘signal transducer and activator of transcription’ family
[17]. Cytokines, in the presence of glucocorticoids, regu-
late aromatase gene expression via the PI.4. In malignant
breast tissue the important observation was made that
promoter switching occurred such that aromatase gene
expression is regulated by PII and PI.3 to a greater extent
than PI.4 [18,19]. Expression from PII and PI.3 is regu-
lated by cAMP and factors that regulate cAMP levels.
Prostaglandin E2 (PGE2) is thought to be an important
regulator of aromatase gene expression via PII and PI.3
[20]. Although the mechanism by which promoter switch-
ing in malignant breast tissue occurs remains to be eluci-
dated, it is likely that the use of alternative promoters
confers a growth advantage on the tumor. Studies are cur-
rently in progress to determine the relative abilities of IL-6
and PGE2 to simulate aromatase activity in fibroblasts
derived from normal and malignant breast tissues. Regula-
tion of aromatase activity in malignant tissues, however, is
likely to be highly complex. It has recently been found that
PGE2 may act, at least in part, by stimulating IL-6 produc-
tion in fibroblasts derived from normal and malignant
breast tissues [21].
Estrone sulfatase
Much of the estrone derived from androstenedione is con-
verted to estrone sulfate by estrone- and phenol-sulpho-
transferases. Estrone sulfate is hydrophilic and circulates
at much higher levels than that of the unconjugated estro-
gens and acts as a reservoir for the formation of active
steroids via the action of estrone sulfatase (E1-STS).
Expression of E1-STS mRNA is much higher in malignant
than in normal breast tissue [22]. The determination of
E1-STS mRNA expression in breast tumors has prognos-
tic significance and a high level of expression is associ-
ated with a poor prognosis [23].
E1-STS belongs to a family of 11 sulfatase enzymes but
only one steroid sulfatase is thought to exist which is able
to hydrolyse both aryl (e.g. estrone sulfate) and alkyl (e.g.
dehydroepiandrosterone sulfate [DHEA-S]) substrates.
Recently DHEA-S was shown to be a potent stimulator ofthe growth of MCF-7 breast cancer cells [24]. The DHEA-
S stimulated growth of these cells could not be blocked
by aromatase inhibitors. This finding provides convincing
evidence for an alternative pathway by which the growth
of hormone-dependent tumors might be stimulated.
DHEA-S is converted to DHEA, by steroid sulfatase, and
DHEA can be subsequently reduced to androstenediol, a
steroid with potent estrogenic properties.
Research into the regulation of E1-STS expression and
activity is still in its infancy. While cytokines such as IL-6
and TNF-α can increase the activity of this enzyme, no
effect of these cytokines at the expression level has so far
been detected [25]. Thus, these cytokines may act to
increase post-translational modifications of the enzyme.
Alternatively, it has been postulated that IL-6 and/or TNF-α
may affect membrane permeability, thereby increasing
substrate availability and hence enzyme activity.
Estradiol-17β β-hydroxysteroid dehydrogenase
Type 1
Estrone can be formed as a result of aromatase or E1-STS
activity but to achieve its full biological potency it must be
reduced to estradiol; this reaction is mediated by 17β-
HSD Type 1. There are 9–10 members of the 17β-HSD
family of enzymes, which regulate ligand availability to
either the estrogen or androgen receptors [26]. Other
reactions catalysed by members of the 17β-HSD family
include the reduction of DHEA to androstenediol (Types 1
and 5), androstenedione to testosterone (Types 3 and 5)
and the inactivation of estradiol (mainly Type 2).
When high estradiol concentrations were initially detected
in breast tumors it was not readily apparent why such high
levels should exist in tumors. The overall peripheral metab-
olism of estrogens strongly favors the inactivation of estra-
diol rather than the conversion of estrone to estradiol.
Using an isotopic infusion technique in women with breast
cancer, estrone was found to be preferentially converted
to estradiol in tumor tissue [27]. A search for factors that
could preferentially stimulate the conversion of estrone to
estradiol identified IL-6 and TNF-α as key regulators
[28,29]. In addition, insulin-like growth factor Type I and
an albumin-like molecule isolated from breast tumor
cytosol, were also found to regulate the conversions of
estrone to estradiol [30]. In MCF-7 breast cancer cells
most cytokines and other factors have been found to pref-
erentially stimulate the conversions of estrone to estradiol.
In another breast cancer cell line, ZR-75-1, IL-4 and IL-6
were found to markedly stimulate the inactivation of estra-
diol, thus the effects of cytokines on 17β-HSD activity vary
in different cell lines [31]. However, in view of the
increased conversion of 3H estrone to 3H estradiol
detected in breast tumors [9] and the high estradiol con-
centrations in tumors [3,4], it would appear that overall
cytokines must act in vivo to stimulate estrogen synthesis.
Co-ordination of breast tumor estrogen
synthesis
It is now evident that cytokines, growth factors and PGE2
have crucial roles in regulating estrogen synthesis in
breast tumors. IL-6 and TNF-α can stimulate the activities
of all the enzymes involved in estrogen synthesis; PGE2 is
important in regulating aromatase gene expression in
malignant tissues (Fig. 1). It is likely that the activities of
the aromatase, E1-STS and estradiol dehydrogenase
Type 1 are increased in a co-ordinated manner by the
actions of cytokines and PGE2. Such a mechanism may
account for the high concentrations of estradiol that are
detected in breast tumors.
Origin of cytokines
The important role that cytokines have in regulating breast
tumor estrogen synthesis stimulated research into the
origin of such factors. There is convincing evidence that
IL-6 is produced by fibroblasts derived from normal and
malignant breast tissues. Conditioned medium collected
from lipopolysaccharide-stimulated monocytes and lym-
phocytes was also found to markedly stimulate aromatase
activity in breast-tissue-derived fibroblasts [8]. This finding
suggests that these cells may be an important source of
stimulatory cytokines.
Recent studies by Daynes [32] and Rook [33] have investi-
gated factors involved in regulating cytokine production by
Th cells. Their studies have suggested that the balance of
the adrenal androgen, DHEA, to that of glucocorticoids
determines the type of cytokines produced by Th lympho-
cytes. Th cells can progress to either a Th1 or Th2 pheno-
type and each type of Th cell secretes a characteristic
profile of cytokines; IL-6 is produced by Th2 cells. High
levels of DHEA are associated with a Th1 response while a
predominantly glucocorticoid environment promotes a Th2-
type response. Production of DHEA starts to decline at
about the age of 25 years and thus in older subjects there is
a switch from a Th1- to Th2- type of environment. IL-4 is a
Th2-type cytokine and has been shown to induce 3β-
HSD/isomerase activity in breast cancer cells which
increases the conversion of DHEA to androstenedione [31].
As androstenedione is a substrate of the aromatase, this
could be another mechanism by which cytokines increase
estrogen synthesis in breast tumors. Activation of the
immune response and inflammation may also support tumor
formation by inducing a Th2-type response [34]. In addition
to the role that IL-6 has in stimulating estrogen synthesis, it
is also a pro-angiogenic factor, supporting the growth of
new blood vessels that are essential for tumor growth.
Implication for the etiology of breast cancer
The identification of cytokines as having an important role
in regulating estrogen synthesis in breast tissues has pro-
vided new insight into understanding some aspects of the
etiology of breast cancer. It is well established that breast
Available online http://breast-cancer-research.com/content/4/2/65cancer occurs more frequently in older, postmenopausal
women and that obese postmenopausal women are at an
increased risk of developing breast cancer. Several
studies have now shown that plasma IL-6 levels increase
with aging [35]. It is possible that the decrease in DHEA
production that occurs with aging induces a Th2-type
cytokine response that is associated with increased pro-
duction of IL-6. There is also evidence that production of
IL-6 and TNF-α may be influenced by body weight [36].
The peripheral conversion of androstenedione to estrone
is increased in older, overweight subjects. It is now appar-
ent that changes in cytokine production that are related to
obesity and aging, by increasing aromatase, E1-STS and
estradiol dehydrogenase Type 1 activities, may account
for the increased peripheral production of estrogens in
such subjects. Although controversial, there is evidence
that stress may also increase the risk of developing breast
cancer [37]. By increasing glucocorticoid production,
stress favors a Th2-type cytokine production and an
increase in IL-6 levels. The incidence of breast cancer is
reduced in immunosuppressed women [38]. As cytokine
production is also reduced in immunosuppressed women,
this finding supports the concept that cytokines have an
important role in breast cancer, possibly acting via stimula-
tion of estrogen synthesis [39,40].
Conclusion
A major stimulus to identifying the factors that regulate
estrogen synthesis in breast tumors is the insight that
such knowledge may aid the development of novel drugs
for the prevention or treatment of breast cancer. Prelimi-
nary investigations have already revealed that it may be
possible to use small peptides or IL-6 variants to block the
ability of IL-6 to stimulate aromatase activity. If the adrenal
androgen, DHEA, does have an important role in regulat-
ing the Th1:Th2 balance it would seem appropriate to
examine whether the administration of this steroid can be
used to promote a Th1 response. Alternatively, it may
prove feasible to devise an immunisation strategy that
would favor a Th1-type response. In view of the relatively
short-term responses for most current therapies, the
development of such novel strategies may offer new hope
for the treatment of breast cancer.
References
1. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC,
Simpson ER: Aromatization of androstenedione by human
adipose tissue stromal cells in monolayer culture. J Clin
Endocrinol Metab 1981, 53:412-417.
2. Miller WR, Forrest APM: Oestradiol synthesis from C19
steroids by human breast cancer. Br J Cancer 1974, 33:16-18.
3. Bonney RC, Reed MJ, Davidson K, Beranek, PA, James VHT: The
relationship between 17β β-hydroxy-steroid dehydrogenase activ-
ity and oestrogen concentrations in human breast tumours and
in normal breast tissue. Clin Endocrinol 1983, 19:727-739.
4. Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J,
Milewicz A: On the significance of in situ production of oestro-
gens in human breast cancer tissues. J Steroid Biochem Mol
Biol 1992, 41:891-896.
5. Simpson ER, Ackerman GE, Smith ME, Mendelson CR: Estrogen
formation in stromal cells of adipose tissue of women: induc-
tion by glucocorticoids. Proc Natl Acad Sci USA 1981, 78:5690-
5694.
Breast Cancer Research    Vol 4 No 2 Purohit et al.
Figure 1
Estrogen synthesis in breast tissues. Three enzyme complexes are involved in estrogen synthesis in breast tissues: (1) Aromatase (Arom) which
converts androstenedione (A) to estrone (E1); (2) estrone sulfatase (E1-STS) which hydrolyses estrone sulfate (E1-S) to E1 and (3) estradiol-17β-
hydroxysteroid dehydrogenase (17β-HSD) Type 1 which reduces E1 to the biologically active estrogen, estradiol (E2). 17β-HSD Type 2 is involved
in the inactivation of E2. Higher levels of aromatase activity are detected in stromal fibroblasts. In ‘normal’ breast tissue, aromatase gene expression
is thought to be regulated to a greater extent by promoter (P)I.4 expression, which is stimulated by cytokines such as IL-6 and tumor necrosis
factor (TNF)-α. In malignant breast tissues, aromatase gene expression is thought to be regulated to a greater extent by PI.3 and PII, expression of
which is stimulated by cAMP and factors such as prostaglandin (PG) E2, which increase cAMP levels. Cytokines such as IL-6 and TNF-α also
increase 17β-HSD Type 1 activity, while their effect on E1-STS activity may be indirect.
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